Auranofin, (AF), a gold(I) complex in clinical use for the therapy of rheumatoid arthritis, is reported here to produce remarkable bactericidal effects in vitro against Staphylococcus sp. Noticeably, a similar antimicrobial action and potency are also noticed toward a few methicillin-resistant Staphylococcus aureus strains but not toward Escherichia coli. The time and concentration dependencies of the antimicrobial actions of AF have been characterized through recording time kill curves, and a concentration dependent profile highlighted. Overall, the present results point out that auranofin might be quickly and successfully repurposed for the treatment of severe bacterial infections due to resistant Staphylococci.
MARZO, TIZIANO (Secondo)
|Autori:||Maria Iris, Cassetta; Marzo, Tiziano; Stefania, Fallani; Andrea, Novelli; Luigi, Messori|
|Titolo:||Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections|
|Anno del prodotto:||2014|
|Digital Object Identifier (DOI):||10.1007/s10534-014-9743-6|
|Appare nelle tipologie:||1.1 Articolo in rivista|